A Partially Randomized, Sequential Cohort, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Subcutaneous Ravulizumab Coadministered With rHuPH20 in Healthy Adult Volunteers
Latest Information Update: 24 Jan 2024
At a glance
- Drugs Hyaluronidase (Primary) ; Ravulizumab (Primary)
- Indications Acute kidney injury; Dermatomyositis; Haemolytic uraemic syndrome; IgA nephropathy; Lupus nephritis; Myasthenia gravis; Neuromyelitis optica; Paroxysmal nocturnal haemoglobinuria; Thrombotic microangiopathies
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Alexion AstraZeneca Rare Disease
- 02 Jun 2022 New trial record